Back to top
more

Cassava Sciences (SAVA)

(Delayed Data from NSDQ)

$22.34 USD

22.34
1,072,481

+0.61 (2.81%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $22.33 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Cassava (SAVA) Down as Quanterix Issues Statement on AD Study

Cassava (SAVA) tanks yet again after Quanterix stated that it did not interpret the test results or prepare the data charts presented by the former.

Cassava (SAVA) Responds to Charges Against its Integrity in AD Study

Cassava (SAVA) plunges following charges against its scientific integrity in developing a drug for Alzheimer's disease. The company responds to the same.

Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?

Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.

Biotech Stock Roundup: BIIB's AD Drug Update, CVAC's Decline on Vaccine Data & More

The biotech sector was in focus last week with pipeline updates from Biogen (BIIB) and CureVac (CVAC), among others.

Cassava (SAVA) Stock Up on Alzheimer's Candidate Update

Cassava Sciences' (SAVA) completes enrollment in its open-label study on simufilam. It plans to begin two pivotal phase III studies on simufilam in the second half of 2021.

Cassava Sciences (SAVA) is Overbought: Is A Drop Coming?

Cassava Sciences (SAVA) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Cassava Sciences, Inc. (SAVA) Gains As Market Dips: What You Should Know

Cassava Sciences, Inc. (SAVA) closed at $79.65 in the latest trading session, marking a +1.34% move from the prior day.

Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day

Urban Outfitters, Travelzoo, Eli Lilly, Cassava Sciences and Annovis Bio highlighted as Zacks Bull and Bear of the Day

Kinjel Shah headshot

3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug

FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.

Aditi Saraogi headshot

Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock?

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

Kevin Cook headshot

Alzheimer's Disease: 5 Stocks on Biotech Radars

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $34.85, marking a -0.68% move from the previous day.

Has Cassava Sciences (SAVA) Outpaced Other Medical Stocks This Year?

Is (SAVA) Outperforming Other Medical Stocks This Year?

The Zacks Analyst Blog Highlights: Denbury, Riot Blockchain, Marathon Digital Holdings, Silvergate Capital and Cassava Sciences

The Zacks Analyst Blog Highlights: Denbury, Riot Blockchain, Marathon Digital Holdings, Silvergate Capital and Cassava Sciences

Sweta Killa headshot

A Year Into the COVID-19 Pandemic: 5 Stock Winners

Though the U.S. economy is far from pre-pandemic levels, it has shown solid improvement. Meanwhile, the stock market has strongly bounced back and reached new milestones.

Cassava Sciences (SAVA) Up More Than 600% YTD: Here's Why

Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, simufilam.

Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?

Is (SAVA) Outperforming Other Medical Stocks This Year?

ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss

ChemoCentryx Inc. (CCXI) reports a wider-than-expected loss in the fourth quarter and misses on sales.

Amarin (AMRN) Q4 Earnings & Revenues Top, Vascepa Sales Solid

Amarin's (AMRN) revenue growth in the fourth quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Implied Volatility Surging for Cassava Sciences (SAVA) Stock Options

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat

United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.

Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull

Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.

Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $52.37, moving -1.23% from the previous trading session.

Cassava Sciences (SAVA) to Post Q4 Earnings: What's in Store?

Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.